Browse the evidence

Two-year surgical complications were lower among GLP-1 RA users in BMI 35 to 39.9 and ≥40 groups.

GLP-1 RA may be beneficial for reducing long-term surgical complications in higher BMI patients.

GLP-1 RA use was associated with significantly reduced risk of revision at 10 years in the 25.0 to 29.9 BMI group.

Consideration of GLP-1 RA may improve long-term surgical outcomes in patients with lower BMI.

Incretin-based therapy reduced all-cause mortality by 18%.

Incretin-based therapies may improve survival rates in overweight or obese individuals.

The total daily dose (TDD) of insulin decreased from 183 ± 98 units to 143 ± 99 units over 6 months (P < 0.001).

Clinicians may consider semaglutide as a viable option to reduce insulin requirements in T2DM patients.

GLP-1 receptor agonists (GLP-1RAs) may influence skeletal muscle through anti-inflammatory, antioxidant, and mitochondrial-supportive mechanisms.

Practitioners should consider the potential muscle-preserving effects of GLP-1RAs in patients at risk for sarcopenia.

GLP-1RAs have shown muscle-preserving properties in experimental models of aging, sarcopenic obesity, and chronic disease.

GLP-1RAs may be beneficial in preserving muscle in specific populations, such as the elderly or those with chronic diseases.

Optimal selection of anti-obesity therapy requires consideration of patient factors and medication-related factors.

Healthcare providers should assess individual patient needs when prescribing anti-obesity medications.

The expanding array of anti-obesity medications provides valuable treatment options alongside lifestyle interventions and surgical approaches.

Integrating medications with lifestyle changes and surgical options can enhance obesity management.

Obesity leads to inflammation and altered hormone production that can promote cancer development.

Understanding the hormonal and inflammatory changes in obesity can help in developing targeted interventions for cancer prevention.

Semaglutide is the most cost-effective treatment option in the severe obesity patient population and in first-tier cities in China.

In specific urban populations with severe obesity, semaglutide may be a preferred treatment option.

Lifestyle management was the most likely to be cost-effective under the willingness-to-pay threshold.

Lifestyle interventions should be prioritized for cost-effective obesity management.

Recent findings highlight promising signaling/targets for managing body weight, including appetite inhibition and energy expenditure.

Practitioners should focus on these signaling pathways for obesity interventions.

Semaglutide was associated with a reduction in heavy drinking days by -41.1 percentage points from baseline compared to placebo, which had a reduction of -26.4 percentage points.

Semaglutide may be a viable treatment option for reducing heavy drinking in patients with alcohol use disorder and obesity.

Semaglutide improved heart failure symptoms and physical limitations in participants with obesity-related HFpEF.

Practitioners can consider semaglutide as an effective treatment for improving symptoms in patients with obesity-related HFpEF.

Weight loss in the GLP-1 RA group was directly associated with bone loss at the total hip (TH) and femoral neck (FN).

Weight management strategies may need to consider potential impacts on bone health.

Semaglutide treatment shows significant interactions based on sex at both 1.7 mg and 2.4 mg doses compared to placebo.

Clinicians should consider sex as a factor when prescribing semaglutide for weight loss.

Semaglutide 2.4 mg shows significant treatment interactions based on the presence of type 2 diabetes and dyslipidemia at baseline compared to placebo.

Healthcare providers should assess comorbidities when evaluating the potential effectiveness of semaglutide.

The PMR diet was found to be safe, with no adverse events attributed to study participation.

The PMR diet can be safely implemented in clinical settings for stroke patients.

Participants in the PMR group reported barriers to weight loss, including food cravings and dislike for some food products.

Addressing food preferences and cravings may enhance adherence to PMR diets.

HEC-C046, with high GCG receptor selectivity, shows significant weight loss and improvement in MASLD parameters but raises safety concerns.

Practitioners should consider the balance between efficacy and safety when using dual receptor agonists.

HEC-C052, with the lowest GCG agonism, is less effective for weight loss compared to semaglutide.

Semaglutide may be preferred over HEC-C052 for weight loss in certain populations.

Randomized trials with liraglutide and semaglutide have shown reductions in major adverse cardiovascular events.

These medications may be beneficial for patients at high risk of cardiovascular events.

Semaglutide improved lipid parameters, including reductions in LDL cholesterol and non-HDL cholesterol levels.

Semaglutide may be beneficial for improving lipid profiles in patients with T2DM.

Visceral and ectopic fat accumulation strongly predicts adverse lipid patterns, insulin resistance, and cardiovascular events.

Focus on reducing visceral and ectopic fat to improve lipid profiles and reduce cardiovascular risk.